CA Patent

CA2962075A1 — Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor

Assigned to Janssen Pharmaceutica NV · Expires 2016-03-31 · 10y expired

What this patent protects

Disclosed herein are methods of identifying a cancer patient that will be responsive to treatment with a fibroblast growth factor receptor (FGFR) inhibitor and methods of treating cancer patients. The methods involve evaluating a biological sample from the patient for the presenc…

USPTO Abstract

Disclosed herein are methods of identifying a cancer patient that will be responsive to treatment with a fibroblast growth factor receptor (FGFR) inhibitor and methods of treating cancer patients. The methods involve evaluating a biological sample from the patient for the presence of one or more FGFR mutants from a FGFR mutant gene panel. Kits and primers for identifying the presence of one or more FGFR mutant genes in a biological sample are also disclosed herein.

Drugs covered by this patent

Patent Metadata

Patent number
CA2962075A1
Jurisdiction
CA
Classification
—
Expires
2016-03-31
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.